Today’s Trademark – oNKo-innate

The trademark of ONKO-INNATE is owned by oNKo-innate Pty Ltd was registered in USTPO bearing registration number 6617149 on Jan. 18, 2022.

With a strong background in academic research, oNKo-innate has emerged as one of Australia’s leading independent immuno-oncology companies. From an initial specialization in natural killer cell therapies, we have expanded to prosecute some of the boldest targets in immuno-oncology. With three integrated platforms spanning target discovery, computational biology, and therapeutic discovery and development, our unbiased approach allows us to pursue any target, in potentially any cell type.

Leveraging our technical prowess and a deep understanding of the immune system, we have developed novel pipeline assets that tackle some of the major obstacles in solid tumor therapy, including toxicity and treatment resistance. While oncology is our primary focus, our platforms have broader applications in immunology, including autoimmune disease.